RedHill Biopharma (NASDAQ:RDHL) is scheduled to post its quarterly earnings results before the market opens on Thursday, February 22nd. Analysts expect RedHill Biopharma to post earnings of ($0.65) per share for the quarter.
RedHill Biopharma (NASDAQ:RDHL) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.18). The company had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.27 million. On average, analysts expect RedHill Biopharma to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
RedHill Biopharma (NASDAQ RDHL) opened at $5.90 on Thursday. The firm has a market cap of $123.81, a price-to-earnings ratio of -2.19 and a beta of 0.74. RedHill Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $11.25.
COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/15/redhill-biopharma-rdhl-scheduled-to-post-earnings-on-thursday.html.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.